DrugPatentWatch Database Preview
DOXYCYCLINE HYCLATE - Generic Drug Details
What are the generic drug sources for doxycycline hyclate and what is the scope of patent protection?
Doxycycline hyclate
is the generic ingredient in fifteen branded drugs marketed by Pliva, Mayne Pharma Intl, Warner Chilcott, Medicis, Almirall, Teva, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alembic Pharms Ltd, Amneal Pharms, Chartwell Life Sci, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Mylan, Par Pharm, Pvt Form, Ranbaxy, Sun Pharm Industries, Superpharm, Watson Labs, Zydus Pharms, Collagenex, Pfizer, Fresenius Kabi Usa, Rachelle, Mylan Labs Ltd, West-ward Pharms Int, Tolmar, Mayne Pharma, Actavis Elizabeth, Heritage Pharms Inc, Impax Labs Inc, Mylan Pharms Inc, Prinston Inc, Amneal Pharms Co, Apotex Inc, Cadila, Caribe Holdings, Emcure Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Lannett Co Inc, Larken Labs, Lupin Ltd, Mayne Pharma Inc, Novel Labs Inc, Vintage Pharms, Chartwell Pharma, and Galderma Labs Lp, and is included in seventy-seven NDAs. There are five patents protecting this compound and seven Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Doxycycline hyclate has two patent family members in two countries.
There are twenty-eight drug master file entries for doxycycline hyclate. Seventy-seven suppliers are listed for this compound.
Summary for DOXYCYCLINE HYCLATE
| International Patents: | 2 |
| US Patents: | 5 |
| Tradenames: | 15 |
| Applicants: | 52 |
| NDAs: | 77 |
| Drug Master File Entries: | 28 |
| Suppliers / Packagers: | 77 |
| Bulk Api Vendors: | 127 |
| Clinical Trials: | 8 |
| Patent Applications: | 3,425 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for DOXYCYCLINE HYCLATE |
| Drug Sales Revenues: | Drug sales revenues for DOXYCYCLINE HYCLATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DOXYCYCLINE HYCLATE |
| DailyMed Link: | DOXYCYCLINE HYCLATE at DailyMed |
Recent Clinical Trials for DOXYCYCLINE HYCLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Royal Alexandra Hospital | Phase 2 |
| University of Alberta | Phase 2 |
| PolyPid Ltd. | Phase 1/Phase 2 |
Recent Litigation for DOXYCYCLINE HYCLATE
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC | 2017-11-09 |
| WARNER CHILCOTT LABORATORIES IRELAND LIMITED v. MYLAN PHARMACEUTICALS INC. | 2009-05-01 |
| WARNER CHILCOTT LABORATORIES IRELAND LIMITED v. IMPAX LABORATORIES, INC. | 2009-03-18 |
Pharmacology for DOXYCYCLINE HYCLATE
| Drug Class | Tetracycline-class Drug |
Synonyms for DOXYCYCLINE HYCLATE
| (1S,4aS,11R,11aR,12S,12aR)-3-carbamoyl-2,4a,5,7,12-pentahydroxy-N,N,11-trimethyl-4,6-dioxo-1,4,4a,6,11,11a,12,12a-octahydrotetracen-1-aminium chloride--ethanol--water (2/1/1) |
| (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride |
| (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride |
| (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride |
| (2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione; ethanol; hydrate; dihydrochloride |
| (4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide |
| (4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione |
| (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)- 3,5,10,12,12a-pentahydroxy- 6-methyl- 1,11-dioxo- 1,4,4a,5,5a,6,11,12a-octahydrotetracene- 2-carboxamide hydrochloride hemiethanolate hemihydrate |
| (4s,4ar,5s,5ar,6r,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide |
| (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide |
| (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide - ethanol (2:1) dihydrochloride hydrate |
| (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide compound with ethanol (2:1) dihydrochloride hydrate |
| (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide |
| (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride |
| 100929-47-3 |
| 10592-13-9 |
| 10592-13-9 (. HCl) |
| 10597-92-9 |
| 1368-EP2269978A2 |
| 1368-EP2269985A2 |
| 1368-EP2269991A2 |
| 1368-EP2284150A2 |
| 1368-EP2284151A2 |
| 1368-EP2284152A2 |
| 1368-EP2284153A2 |
| 1368-EP2284155A2 |
| 1368-EP2284156A2 |
| 1368-EP2284164A2 |
| 1368-EP2287140A2 |
| 1368-EP2287148A2 |
| 1368-EP2287150A2 |
| 1368-EP2289871A1 |
| 1368-EP2295402A2 |
| 1368-EP2295419A2 |
| 1368-EP2298732A1 |
| 1368-EP2301534A1 |
| 1368-EP2301912A2 |
| 1368-EP2301913A1 |
| 1368-EP2301914A1 |
| 1368-EP2301916A2 |
| 1368-EP2305637A2 |
| 1368-EP2305640A2 |
| 1368-EP2308863A1 |
| 1368-EP2311451A1 |
| 1368-EP2311796A1 |
| 1368-EP2311797A1 |
| 1368-EP2311798A1 |
| 1368-EP2311799A1 |
| 1368-EP2316450A1 |
| 17086-28-1 (mono-hydrate) |
| 19XTS3T51U |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS) |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride, (4S,4aR,5S,5aR,6R,12aS)-, compd. with ethanol, hydrate (2:2:1:1) |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- |
| 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S,4aR,5S,5aR,6R,12aS)- |
| 2-Naphthacenecarboxamide, 4-alpha-S-(dimethylamino)-1,4,4a-alpha-5,5a-alpha,6,11,12a-octahydro-3,5-alpha,10,12,12a-alpha-pentahydroxy-6-alpha-methyl-1,11-dioxo- |
| 2-Naphthacenecarboxamide, 4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, hydrochloride |
| 2-Naphthacenecarboxamide, 4beta-(dimeethylamino)-1,4,4abeta,5,5abeta,6,11,12a-octahydro-3,5beta,10,12,12abeta-pentahydroxy-6beta-methyl-1,11-dioxo-, monohydrochloride, compd. with ethyl alcohol (2:1), monohydrate |
| 2-Naphthacenecarboxamide,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, monohydrochloride, (4S,4aR,5S,5aR,6R,12aS)-, compd. with ethanol (2:1), monohydrate (9CI) (CA INDEX NAME) |
| 2387AH |
| 24390-14-5 |
| 2C22H24N2O8.C2H6O.2ClH.H2O |
| 2C22H24N2O8.C2H6O.H2O |
| 334895S862 |
| 390D145 |
| 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate |
| 4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide - ethanol (2:1) dihydrochloride hydrate |
| 4-Epioxytetracycline, 6-deoxy- |
| 41411-66-9 (6-epimer, mono-hydrochloride) |
| 4182Z6T2ET |
| 5-Hydroxy-alpha-6-deoxytetracycline |
| 5-Hydroxy-alpha-6-deoxytetracycline monohydrate |
| 53108-42-2 |
| 564-25-0 |
| 564D250 |
| 6-alpha-Deoxy-5-oxytetracycline |
| 6-Deoxy-5-hydroxytetracycline hydrochloride hemihydrate |
| 6-Deoxyoxytetracycline |
| 6-Deoxytetracycline |
| 6-Desoxy-5-hydroxytetracycline hydrochloride hemihydrate hemiethanolate |
| 61281-03-6 |
| 62149-53-5 |
| 69935-17-7 (mono-hydrochloride, di-hydrate) |
| 6alpha-Deoxy-5-oxytetracycline |
| 7164-70-7 |
| 7264-10-0 |
| 94088-85-4 (calcium salt (1:2)) |
| AB00053465_04 |
| AB00053465_05 |
| AB00053465-03 |
| AB08 (*Fosfatex) |
| AC-12044 |
| AC-6017 |
| AC1L1WYQ |
| AC1NQXW7 |
| AC1NQZPV |
| AC1NTTH2 |
| AC1NUYS5 |
| AC1NUYS8 |
| Acticlate |
| Acticlate CAP |
| AK175707 |
| AK321970 |
| AKOS015900372 |
| AKOS015924649 |
| AKOS025310153 |
| AKOS025402170 |
| alpha-6-Deoxy-5-hydroxytetracycline |
| alpha-6-Deoxyoxytetracycline |
| alpha-6-Deoxyoxytetracycline monohydrate |
| alpha-6-Tetracycline monohydrate |
| alpha-Doxycycline |
| Alti-Doxycycline |
| AN-18097 |
| Anhydrous doxycycline |
| API0002491 |
| API0002492 |
| Apo-Doxy |
| AS-13499 |
| Atridox |
| Azudoxat |
| BCBcMAP01_000024 |
| Biocamycin |
| bis((4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide) ethanol hydrate dihydrochloride |
| BMY 28689 |
| BMY-28689 |
| BMY28689 |
| BSPBio_001936 |
| BU 3839T |
| BU-3839T |
| C-0055 |
| C06973 |
| C22H24N2O8.HCl.0.5H2O.0.5C2H6O |
| C22H25ClN2O8 |
| CAS-10592-13-9 |
| CCG-204498 |
| CCG-38949 |
| CHEBI:34730 |
| CHEBI:50845 |
| CHEBI:652992 |
| CHEMBL1200567 |
| CHEMBL1256723 |
| CHEMBL1433 |
| CHEMBL3989740 |
| CHEMBL436921 |
| controlled-release doxycycline hy-clate |
| CS-2632 |
| D 9891 |
| D02129 |
| D07876 |
| D07877 |
| D4116 |
| DB00254 |
| Dentista |
| Deoxy-5-hydroxytetracycline hydrochloride |
| Deoxymykoin |
| Deoxyoxytetracycline hydrochloride |
| DivK1c_000345 |
| DMSC (*Fosfatex) |
| Doryx |
| Doryx (TN) |
| Doryx Mpc |
| Dossiciclina |
| Dossiciclina [DCIT] |
| DOXCYCLINE ANHYDROUS |
| Doxiciclina |
| Doxiciclina [INN-Spanish] |
| Doxiciclina [Italian] |
| Doxigalumicina |
| Doxitard |
| Doxivetin |
| Doxteric |
| DOXY |
| Doxy 100 |
| DOXY 200 |
| Doxy-Caps |
| Doxy-II |
| Doxy-Lemmon |
| Doxy-Puren |
| Doxy-tablinen |
| Doxy-Tabs |
| Doxycen |
| Doxychel |
| Doxychel (TN) |
| Doxychel Hyclate |
| Doxycin |
| Doxycyclin |
| doxycycline |
| Doxycycline (200mg/day) or Placebo |
| Doxycycline (anhydrous) |
| Doxycycline (hyclate) |
| Doxycycline (hydrochloride) |
| Doxycycline (INN) |
| Doxycycline (internal use) |
| Doxycycline (TN) |
| Doxycycline [USAN:INN:BAN] |
| DOXYCYCLINE CALCIUM |
| Doxycycline HCl |
| Doxycycline Hyclate (100 mg) |
| Doxycycline hyclate (internal use) |
| Doxycycline hyclate (USP) |
| Doxycycline hyclate [USAN:USP] |
| doxycycline hyclate 20 mg twice daily |
| Doxycycline hydrochloride |
| Doxycycline Hydrochloride [JAN] |
| Doxycycline hydrochloride hemiethanolate hemihydrate |
| Doxycycline hydrochloride hydrate (JP17) |
| DOXYCYCLINE HYLATE |
| Doxycycline-Chinoin |
| Doxycycline, Antibiotic for Culture Media Use Only |
| Doxycycline, HCl |
| Doxycycline, Hyclate |
| Doxycyclinum |
| Doxycyclinum [INN-Latin] |
| Doxylin |
| Doxyprex |
| Doxysol |
| Doxytec |
| Doxytetracycline |
| DS-9077 |
| DSSTox_CID_25405 |
| DSSTox_GSID_45405 |
| DSSTox_RID_80856 |
| DTXSID0037653 |
| DTXSID1045405 |
| DTXSID4041020 |
| Ecodox |
| EINECS 209-271-1 |
| EINECS 234-198-7 |
| Ethanol, compd. with (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride (1:2), monohydrate |
| EU-0100405 |
| FT-0603476 |
| GS-3065 |
| GS-3065 (*monohydrate) |
| GTPL6464 |
| HMS1920I20 |
| HMS2090E06 |
| HSDB 3071 |
| HY-N0565A |
| Hydramycin |
| I015 |
| I455 |
| IDI1_000345 |
| Idocyklin |
| Investin |
| J-000264 |
| J10246 |
| JBIWCJUYHHGXTC-AKNGSSGZSA-N |
| Jenacyclin |
| JRNIHERUNQWMMW-WBYAVNBMSA-N |
| KBio1_000345 |
| KBio2_001287 |
| KBio2_003855 |
| KBio2_006423 |
| KBio3_001156 |
| KBioGR_001133 |
| KBioSS_001287 |
| KS-5254 |
| Liomycin |
| Liviatin |
| LMPK07000001 |
| Lopac0_000405 |
| LP00405 |
| LS-174052 |
| LS-187766 |
| LS-93868 |
| MCULE-4368118692 |
| MCULE-8555113623 |
| Mespafin |
| MFCD07357237 |
| Midoxin |
| MMV000011 |
| MolPort-002-507-423 |
| MolPort-003-666-171 |
| MolPort-005-932-536 |
| MolPort-023-220-303 |
| MolPort-039-338-208 |
| Monodoks |
| Monodox |
| Monodox (*monohydrate) |
| NCGC00016693-01 |
| NCGC00161602-01 |
| NCGC00161602-03 |
| NCGC00161602-04 |
| NCGC00161602-05 |
| NCGC00161602-06 |
| NCGC00188979-01 |
| NCGC00261090-01 |
| NINDS_000345 |
| Nivocilin |
| Novadox |
| Novo-Doxylin |
| NPV78C39GQ |
| NSC-633557 |
| NSC-741421 |
| NSC-756751 |
| NSC633557 |
| NSC741421 |
| NSC756751 |
| Nu-Doxycycline |
| Oracea |
| Oxytetracycline, 6-deoxy- |
| Periostat |
| Periostat (TN) |
| Pharmakon1600-01500266 |
| RETENS |
| Ronaxan |
| Roximycin |
| RPRXAHFLWOCXQL-AKNGSSGZSA-N |
| RUYHIJHUVHIMIR-CVHRZJFOSA-N |
| Samecin |
| SBI-0050391.P004 |
| SC-15766 |
| SCHEMBL1176275 |
| SCHEMBL17826665 |
| SCHEMBL19270298 |
| SCHEMBL40834 |
| SCHEMBL40930 |
| SCHEMBL66828 |
| SGKRLCUYIXIAHR-AKNGSSGZSA-N |
| SMP1_000107 |
| Spanor |
| SPBio_000246 |
| Spectrum_000807 |
| SPECTRUM1500266 |
| Spectrum2_000143 |
| Spectrum3_000408 |
| Spectrum4_000527 |
| Spectrum5_000947 |
| SR-01000075844 |
| SR-01000075844-1 |
| SR-01000075844-7 |
| SR-01000075844-8 |
| Supracyclin |
| SW219440-1 |
| SW219440-2 |
| Tanamicin |
| Tecacin |
| Tetraclean |
| Tetradox |
| Tox21_110566 |
| Tox21_110566_1 |
| Tox21_500405 |
| UNII-19XTS3T51U |
| UNII-334895S862 |
| UNII-4182Z6T2ET |
| UNII-NPV78C39GQ |
| UPCMLD-DP021 |
| UPCMLD-DP021:001 |
| Vibra-tabs |
| Vibra-tabs (TN) |
| Vibradox |
| Vibramycin |
| Vibramycin (*monohydrate) |
| Vibramycin (TN) |
| Vibramycin hyclate |
| Vibramycin hydrochloride |
| Vibramycin Novum |
| Vibramycin, Hyclate |
| Vibramycine |
| Vibravenos |
| Vivox |
| Vivox (*Hyclate) |
| W-105517 |
| WC 2031 |
| Z2791720087 |
| Zenavod |
| ZINC100056779 |
| ZINC100302137 |
| ZINC100611210 |
| ZINC109562088 |
| ZINC16052277 |
Paragraph IV (Patent) Challenges for DOXYCYCLINE HYCLATE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| DORYX | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2017-09-28 |
| DORYX MPC | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2017-09-28 |
| DORYX | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2015-11-05 |
| DORYX MPC | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2015-11-05 |
| DORYX MPC | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2015-07-01 |
| DORYX | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2015-07-01 |
| DORYX | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2014-05-19 |
| DORYX MPC | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2014-05-19 |
| DORYX | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2008-12-19 |
| DORYX MPC | TABLET, DELAYED RELEASE;ORAL | doxycycline hyclate | 050795 | 2008-12-19 |
US Patents and Regulatory Information for DOXYCYCLINE HYCLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-002 | May 6, 2005 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Pvt Form | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE;ORAL | 062631-002 | Jul 24, 1986 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Sun Pharm Industries | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET;ORAL | 065134-001 | May 13, 2005 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| West-ward Pharms Int | DOXYCYCLINE HYCLATE | doxycycline hyclate | INJECTABLE;INJECTION | 062992-002 | Feb 16, 1989 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Hikma Intl Pharms | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE;ORAL | 065103-001 | May 13, 2005 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Chartwell Life Sci | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET;ORAL | 062505-001 | Sep 11, 1984 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DOXYCYCLINE HYCLATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006045152 | Start Trial |
| Australia | 2005299253 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.